Clearpoint Neuro Inc
$ 13.44
-2.89%
12 Jun - close price
- Market Cap 403,060,000 USD
- Current Price $ 13.44
- High / Low $ 14.12 / 13.07
- Stock P/E N/A
- Book Value 0.63
- EPS -1.00
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -1.50 %
- 52 Week High 30.10
- 52 Week Low 8.27
About
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Analyst Target Price
$22.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-17 | 2025-11-06 | 2025-08-12 | 2025-05-13 | 2025-02-26 | 2024-11-07 | 2024-08-07 | 2024-05-07 | 2024-03-12 | 2023-11-09 | 2023-08-08 |
| Reported EPS | -0.32 | -0.27 | -0.21 | -0.21 | -0.22 | -0.2 | -0.18 | -0.16 | -0.16 | -0.19 | -0.2 | -0.29 |
| Estimated EPS | -0.23 | -0.185 | -0.18 | -0.2 | -0.16 | -0.1737 | -0.17 | -0.2 | -0.19 | -0.2 | -0.25 | -0.19 |
| Surprise | -0.09 | -0.085 | -0.03 | -0.01 | -0.06 | -0.0263 | -0.01 | 0.04 | 0.03 | 0.01 | 0.05 | -0.1 |
| Surprise Percentage | -39.1304% | -45.9459% | -16.6667% | -5% | -37.5% | -15.141% | -5.8824% | 20% | 15.7895% | 5% | 20% | -52.6316% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLPT
2026-06-09 14:08:47
Stifel reiterated a Buy rating and a $16.00 price target for Clearpoint Neuro Inc. (NASDAQ:CLPT) after the American Society for Stereotactic and Functional Neurosurgery meeting, noting the company's unique neurosurgery platform and strategic entry into focused ultrasound. Despite a recent earnings miss, Stifel highlighted Clearpoint Neuro's strong revenue growth and emphasized the biopharma industry's interest in partnering with the company for cell and gene therapy.
2026-06-08 20:39:05
ClearPoint Neuro director Timothy T. Richards exercised options for 500 shares of common stock at $10.00 per share, while 376 shares were withheld at $13.30 per share to cover tax obligations. Following these transactions, Richards directly owns 87,322 common stock shares, and the exercised option grant is now fully utilized. This activity is considered a neutral event in terms of filing impact and sentiment, reflecting a routine corporate transaction rather than open-market trading.
2026-06-07 21:40:00
This article analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) providing insights into its near, mid, and long-term outlook. It details three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) and emphasizes the importance of current price action with specific support and resistance levels. The analysis highlights a significant 149.7:1 risk-reward setup for a potential 47.7% gain.
2026-06-02 20:40:30
ClearPoint Neuro director Timothy T. Richards sold 5,415 shares of common stock on June 1, 2026, at an average price of $12.17 per share. This sale was conducted to cover tax liabilities arising from the vesting of 12,417 restricted stock units on May 19, 2026. After the transaction, Richards directly holds 87,198 shares of ClearPoint Neuro common stock.
2026-06-01 20:10:39
A Form 144 notice was filed for ClearPoint Neuro, Inc. (CLPT), proposing the sale of 5,145 common shares with an aggregate value of $62,611.56. These shares originated from restricted stock vesting under a registered plan on May 20, 2026. The filing indicates 29,989,563 shares outstanding as of June 1, 2026, and is an intent to sell, not an executed transaction.
2026-05-31 02:39:33
ClearPoint Neuro has announced a 10-year partnership with Sungkyunkwan University in South Korea to develop focused ultrasound technology, expanding its drug delivery ecosystem and global footprint. This collaboration follows successful preclinical trials demonstrating intravenous delivery of tracers across the blood-brain barrier using a prototype system. The company aims to integrate this technology into its neuro-navigation and robotic platforms, providing a comprehensive solution for targeted drug delivery in neurological disorders.
